Remarks: Thorough Belgian Observational Study of 15 544 Case Records of COVID-19 patients originating from 109 Belgian Hospitals at the height of the Pandemic. It has the numbers to make the case. FULL STORY HERE: https://www.4cmitv.com/2020/09/13/2020-aug-24-low-dose-hydroxychloroquine-therapy-and-mortality-in-hospitalised-patients-with-covid-19-a-nationwide-observational-study-of-8075-participants/
EXERT: In conclusion, in this large nationwide observational study of patients hospitalised with COVID-19, HCQ mono therapy administered at a dosage of 2400 mg over 5 days was independently associated with a significant decrease in mortality compared with patients not treated with HCQ.
This impact was observed both in the early and late treatment groups, suggesting that this benefit might be mediated by immunomodulatory properties, a hypothesis worth addressing as evidence of an antiviral activity of HCQ on SARS- CoV-2 appears increasingly inconsistent.
Considering the availability and cheapness of HCQ, it seems worth further investigating the clinical effect of an optimised dosage of HCQ and designing add- on studies in ongoing trials to monitor, beyond viral shedding and infectiousness, a relevant set of inflammatory markers during the course of SARS-CoV-2 infection.
24 August 2020, 106144 DOI: 10.1016/j.ijantimicag.2020.106144
Authors: Lucy Catteaua; Nicolas Dauby; Marion Montourcy; Emmanuel Bottieau; Joris Hautekiet; Els Goetghebeur; Sabrina van Ierssel; Els Duysburgh; Herman Van Oyen; Chloé Wyndham-Thomas; Dominique Van Beckhoven; Belgian Collaborative Group on COVID-19 Hospital Surveillance
• Hydroxychloroquine (HCQ) 2400 mg over 5 days was used in Belgium for COVID-19.
• Impact of HCQ on mortality among 8075 patients with COVID-19 was assessed.
• Lower mortality in HCQ-treated patients as compared to supportive care.
• Lower mortality was irrespective of symptom duration.
Hydroxychloroquine (HCQ) has been largely used and investigated as therapy for COVID-19 across various settings at a total dose usually ranging from 2400 mg to 9600 mg.
In Belgium, off-label use of low-dose HCQ (total 2400 mg over 5 days) was recommended for hospitalised patients with COVID-19.
We conducted a retrospective analysis of in-hospital mortality in the Belgian national COVID-19 hospital surveillance data. Patients treated either with HCQ mono-therapy and supportive care (HCQ group) were compared with patients treated with supportive care only (no-HCQ group) using a competing risks proportional hazards regression with discharge alive as competing risk, adjusted for demographic and clinical features with robust standard errors.
Of 8075 patients with complete discharge data on 24 May 2020 and diagnosed before 1 May 2020, 4542 received HCQ in mono-therapy and 3533 were in the no-HCQ group. Death was reported in 804/4542 (17.7%) and 957/3533 (27.1%), respectively.
In the multi-variable analysis, mortality was lower in the HCQ group compared with the no-HCQ group [adjusted hazard ratio (aHR) = 0.684, 95% confidence interval (CI) 0.617–0.758].
Compared with the no-HCQ group, mortality in the HCQ group was reduced both in patients diagnosed ≤5 days (n = 3975) and >5 days (n = 3487) after symptom onset [aHR = 0.701 (95% CI 0.617–0.796) and aHR = 0.647 (95% CI 0.525–0.797), respectively].
Compared with supportive care only, low-dose HCQ mono-therapy was independently associated with lower mortality in hospitalised patients with COVID-19 diagnosed and treated early or later after symptom onset.1-s2.0-S0924857920303423-main
Hashtags: #4cminewswire, #BelgianObservationalStudy, #Hydroxychloroquine, #HCQ, #COVID19, #Coronavirus, #4cminews, #4CMiTV, #4CM2020AUG24,
Tags: 4cminewswire, Belgian Observational Study, Hydroxychloroquine, HCQ, COVID-19, Coronavirus, 4cminews, 4CMiTV, #4CM2020AUG24,
4CMINEWS SOCIAL MEDIA:
Gab AU: https://gab.com/4cminewswire/posts/104855392621531673
Dailymotion & Facebook: DEFUNCT SOCIAL MEDIA PLATFORM